Abstract:

In recent years, a variety of critical care clinical studies were developed in China, which arose in different systems or study areas. Chief among these endeavors, the investigation into corona virus disease 2019 (COVID-19) has garnered paramount attention. Some studies demonstrate that RNA capacity of COVID-19 was associated with the severity in clinical status, while others have suggested that immune system dysregulation contributes to the etiology of COVID-19, potentially leading to myocardial damage. Encouragingly, the positive therapeutic outcomes have been reported concerning respiratory strategies. Moreover, sepsis remains a societal burden, and recent research highlighting immunosuppressed neutrophils poses a promising avenue for novel therapeutic interventions. The implementation of hierarchical patient management has facilitated nuanced adjustments in fluid resuscitation strategies. Apart from the conventional research strategies, the contemporary integration of machine learning into phenotypic analysis, particularly in acute respiratory distress syndrome, exhibits promising adaptability. In the future, the individualized diagnosis and treatment principle of precision therapy will become an important guide for the daily work of critical care medicine. This paper offers a comprehensive review of clinical research conducted in China over the past three years, aiming to provide a robust theoretical foundation for future study.

Key words: Intens Care Medicine, Corona virus disease 2019, Clinical study, Therapeutic strategy, Prognosis